Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients

被引：10
|
作者：
Kumar, Lakshin [1 ]
Dasgupta, Sayan [2 ]
Murray-Krezan, Cristina [3 ]
Singh, Nina [4 ,5 ]
Rakita, Robert M. [1 ]
Fisher, Cynthia E. [1 ,6 ]
Limaye, Ajit P. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[3] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA
[4] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Univ Washington, 1959 NE Pacific St, Seattle, WA 98195 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 03期
基金：
美国国家卫生研究院;
关键词：
liver transplant; immunocompromised host; viral infections; cytomegalovirus; antiviral therapy;
D O I：
10.1093/cid/ciad643
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased mortality after adjusting for study arm. Graphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/association-of-cmv-dnaemia-with-long-term-mortality-in-a-randomized-trial-of-preemptive-therapy-pet-and-antiviral-prophylaxis-ap-for-prevention-of-cmv-disease-in-high-risk-donor-seropositive-recipient-se-2480b1a4-e573-43a6-973b-94ea264eed04
引用
收藏
页码：719 / 722
页数：4
相关论文
共 50 条
  • [21] Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis
    Zamora, Danniel
    Dasgupta, Sayan
    Stevens-Ayers, Terry
    Edmison, Bradley
    Winston, Drew J.
    Razonable, Raymund R.
    Mehta, Aneesh K.
    Lyon, G. Marshall
    Boeckh, Michael
    Singh, Nina
    Koelle, David M.
    Limaye, Ajit P.
    JCI INSIGHT, 2024, 9 (18)
  • [22] Prospective Comparison of Cytomegalovirus-Specific Immunity in Donor Seropositive/Recipient Seronegative Liver Transplant Patients Receiving Preemptive Therapy or Antiviral Prophylaxis.
    Limaye, Ajit P.
    Singh, Nina
    Chatterton-Kirchmeier, Sam
    Thuntarug, Mujalin
    Stevens-Ayers, Terry
    Boeckh, Michael
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 249 - 249
  • [23] Prophylaxis vs Preemptive Therapy for Cytomegalovirus (CMV) Disease in (D+/R-) Liver Transplant Recipients
    Bodro, Marta M.
    Llado, Laura L.
    Sabe, Nuria N.
    Niubo, Jordi J.
    Carratala, Jordi J.
    Baliellas, Carme C.
    Fabregat, Joan J.
    LIVER TRANSPLANTATION, 2011, 17 (06) : S235 - S235
  • [24] Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
    Boudreault, A. A.
    Xie, H.
    Rakita, R. M.
    Scott, J. D.
    Davis, C. L.
    Boeckh, M.
    Limaye, A. P.
    TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (03) : 244 - 249
  • [25] Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors
    Winston, DJ
    Busuttil, RW
    TRANSPLANTATION, 2004, 77 (02) : 305 - 308
  • [26] Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
    Kletzmayr, J
    Kotzmann, H
    PopowKraupp, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (02): : 325 - 330
  • [27] Comparison of Prophylaxis and Preemptive Strategy as a Routine CMV Prevention of Seronegative (R-) Liver Transplant Recipients from Seropositive Donors (D plus )
    Camus, Christophe
    Le Neillon, Anne
    Veyer, David
    Latournerie, Marianne
    Bardou-Jacquet, Edouard
    Compagnon, Philippe
    Boudjema, Karim
    LIVER TRANSPLANTATION, 2012, 18 : S243 - S243
  • [28] Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients
    Diaz-Pedroche, Carmen
    Lumbreras, Carlos
    San Juan, Rafael
    Folgueira, Dolores
    Andres, Amado
    Delgado, Juan
    Meneu, Juan Carlos
    Morales, Jose Maria
    Moreno-Elola, Almudena
    Hernando, Susana
    Moreno-Gonzalez, Enrique
    Aguado, Jose Maria
    TRANSPLANTATION, 2006, 82 (01) : 30 - 35
  • [29] Cytomegalovirus (CMV)-Specific T-Cell and Humoral Immune Responses in a Randomized Trial of Preemptive Antiviral Therapy (PET) vs Antiviral Prophylaxis (PRO) After High-Risk CMV D plus R-Liver Transplant (LTx)
    Zamora, D.
    Dasgupta, S.
    Wagener, M.
    Akoto, M.
    Edmison, B.
    Stevens-Ayers, T.
    Winston, D.
    Razonable, R.
    Lyon, G. M.
    Mehta, A.
    Silveira, F. P.
    Koelle, D.
    Boeckh, M.
    Singh, N.
    Limaye, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S603 - S603
  • [30] Prophylaxis of cytomegalovirus (CMV) disease in high-risk renal transplant recipients. A randomized comparison of valacyclovir with oral ganciclovir
    不详
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (02): : 98 - 98
12345